Pharmaceutical, Xoma, Tanox, Novartis, AstraZeneca, and ImClone Business Editors CHICAGO--(BUSINESS WIRE)--March 19, 2003--Biotechnology companies often find themselves twisting in the wind until their next blockbuster drug is approved, making it difficult for investors. But Expert Biotech Investor Nadine Wong highlights one company that brings profit potential to the forefront. Learn about Genentech (NYSE:DNA), as well as OSI Pharmaceutical (NASDAQ:OSIP), Xoma (NASDAQ:XOMA), Tanox (NASDAQ:TNOX), Novartis (NYSE:NVS), AstraZeneca (NYSE:AZN) and ImClone (NASDAQ:IMCL). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/ Here are the highlights from the Featured Expert column: Genentech's (NYSE:DNA) share price has fallen as investors speculate over its cancer drug, Avastin. (Avastin is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF). Investors need to focus on the Phase III clinical data expected to be released in mid-2003, which should clarify matters. The data will include information for 900 patients and a smaller 200 patient supportive Phase III trial studying Avastin in colorectal cancer. Avastin has been widely seen as having the greatest profit potential of any in Genentech's pipeline, because it's the only one of the four big products that Genentech wholly owns. Revenues generated from sales of upcoming biologicals Tarceva, Raptiva and Xolair will be shared with OSI Pharmaceutical (NASDAQ:OSIP), Xoma (NASDAQ:XOMA) and Tanox (NASDAQ:TNOX) and Novartis (NYSE:NVS), respectively. Investors should also watch closely for the release of clinical trial data with Tarceva in non-small cell lung cancer (NSCLC) expected in mid-2003. Tarceva is an epidermal growth factor receptor (EGFR) inhibitor. Based on the mixed clinical results seen in similar EGFR inhibitors such as AstraZeneca's (NYSE:AZN) Iressa and ImClone's (NASDAQ:IMCL) Erbitux, it looks like Wall Street is discounting the potential of Tarceva for this cancer. However, the Oncology Drugs Advisory Committee to the Food and Drug Administration, recently voted 11 to 3 that results in third line advanced NSCLC were "reasonably likely to predict clinical benefit". This means that Tarceva, Iressa and Erbitux still have a chance. Nadine Wong views 2003 as a turning point for Genentech with the odds in favor that the company will introduce one new product to the market. Over the long haul, Genentech has a deep pipeline with 20 projects in development as well as five in Phase III and that the company will likely have little difficulty in achieving its 5-by-5 goal of 25% average annual earnings growth in 1998-05. It's hard to find specific biotech news like this anywhere else! Don't miss your chance to make money in this space though Nadine Wong's detailed commentary and stock recommendations by clicking: http://featuredexpert3bw.zacks.com/ About Zacks Featured Experts To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. Recommendations from Featured Experts Highlighted in FREE Investment Newsletter The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1981 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Nadine Wong Recommends Genentech; and Highlights OSI
Press spacebar to pause and continue. Press esc to stop.